Effect of naproxen co-administration on valproate disposition.
The effects of co-administration of the antiepileptic agent valproic acid (VPA) and the non-steroidal anti-inflammatory drug naproxen (NAP) on their relative dispositions (particularly with respect to glucuronidation) were investigated in human volunteers. Seven healthy males received each drug alone and then in combination (orally twice daily for seven days, 500 mg sodium VPA, 500 mg NAP). On day 7 of each dosing phase, serial plasma and 24 h urine samples were collected for analysis. Co-administration of NAP resulted in significant increases (about 20%, p<0.05) in the apparent plasma clearance of total VPA and in the unbound fraction of VPA in plasma, with the apparent plasma clearance of unbound VPA being unchanged. There were associated increases in the formation clearances to urinary VPA-glucuronide and 3-oxo-VPA, though these were relatively greater for the glucuronidation pathway (and remained significant when formation clearances were calculated using the unbound fraction of drug in plasma). The data thus point to a shift towards glucuronidation as a result of the NAP-induced increase in the unbound fraction of VPA in plasma. By contrast, VPA co-administration caused a decrease (of about 10%, p<0.05) in the apparent plasma clearance of total NAP. Taken in hand with in vitro results showing a VPA-induced displacement (of about 40%) of NAP from plasma protein binding sites, the data strongly support a role for diminished glucuronidation of NAP and its desmethyl metabolite in the presence of co-administered VPA.
Addison
R S
RS
Centre for Studies in Drug Disposition, The University of Queensland, Clinical Sciences Building, Royal Brisbane Hospital, Queensland, Australia. r.addison@medicine.uq.edu.au
Parker-Scott
S L
SL
Hooper
W D
WD
Eadie
M J
MJ
Dickinson
R G
RG
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics* / Q000494:pharmacology*; D000927:Anticonvulsants / Q000493:pharmacokinetics* / Q000494:pharmacology*; D019540:Area Under Curve; D001711:Biotransformation; D004347:Drug Interactions; D008401:Gas Chromatography-Mass Spectrometry; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000493:pharmacokinetics* / Q000494:pharmacology*; D010084:Oxidation-Reduction; D013056:Spectrophotometry, Ultraviolet; D014635:Valproic Acid / Q000493:pharmacokinetics* / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D020719:Glucuronides; D009288:Naproxen; D014635:Valproic Acid